Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease

Bilici A., Karadag B., Doventas A., Erdincler D., Cetinkaya S., Ogut G., ...Daha Fazla

NETHERLANDS JOURNAL OF MEDICINE, cilt.62, sa.10, ss.389-392, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 62 Sayı: 10
  • Basım Tarihi: 2004
  • Dergi Adı: NETHERLANDS JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.389-392
  • İstanbul Üniversitesi Adresli: Evet

Özet

Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.